Member Info for Alak

1st injection in, likely last Friday or Saturday and with RNS out this morning , patient is still alive .

Technically the major safety part of Phase 1 is just about demonstrated. Hopefully patient's progress improves to prove more.

And if phase 1 continues to be proven in all other aspects 🤞, can people afford to not be in?

Well , something to reflect on!!!

Hopefully this is recognised and appreciated by everyone, both private and professional investors.

Gla

Big manipulation of the market yesterday. Seems to be a recurring theme in Hemogenyx share quite often.

Recent postings in the platform making more sense now.

I'm not certain if it makes what happened any more right/ethical, but for once, it came with apparent good intentions. 🤞

Gla

Https://www.globenewswire.com/news-release/2024/12/19/2999616/0/en/CAR-T-Cell-Therapy-Market-to-Surpass-USD-188-84-Billion-by-2034-at-36-8-during-2025-to-2034-Report-by-Polaris-Market-Research.html#:~:text=The%20CAR%2DT%20cell%20therapy,USD%20188.84%20billion%20by%202034.&text=Chimeric%20antigen%20receptor%20(CAR)%20T,system%20for%20attacking%20cancer%20cells.

To think what some of the latest CAR T market evaluation above, means at this stage for Hemogenyx investors and LTHs.

Wouldn't it be better to RNS the 1st injection just before the weekend. It'll give Hemo time to evaluate patient responses. It would reduce the opportunistic speculative sells for a couple of days and who wants to risk it, can take their chances when the market reopens with the thought of how events will unfold before and face the music then.

GLA

Eli Lily and Co just earmarked over 40% of their 53 billion dollar profits of 2024 for research and new marketing in their last month disclosure to their shareholders.

Just something on how the big fishes aims are..

Food for thought..

Hopefully 1st patient infusion is very close.

I agree with Dhub, a modest initial raise of the SP is likely.

But within a few days after, pending on early news/or no news outcome, this picture is highly likely to change (hence binary comments).

As we know phase 1 is mostly about risk assessment.

Then, the change of the SP is going to be both for us as private holders, as well as for those pharma companies that are looking closely at that patient's developments, aiming for a slice of the multi billion dollar market CAR T, deciding is it worth potentially to enter at few % of real value, or wait and risk loosing to someone else.

It's true that LTHs have suffered badly for a long while, but this close to the real news, is it really the time to give up now?

Well, I personally don't think so, but hey, everyone else can do whatever they want.

GLA.

Https://www.linkedin.com/feed/update/urn:li:activity:7275890801342038016?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A7275890801342038016%2C7284282594681053185%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287284282594681053185%2Curn%3Ali%3Aactivity%3A7275890801342038016%29

News Worth considering I thought.

🤞🤞

The FY25 National Defense Authorization Act (NDAA) includes NSCEB-authored authorities and requirements that will position the DoD and Intelligence Community (IC) to maximize the benefits of biotechnology for national defense.

These include the following NSCEB biotechnology provisions:   

 

– An artificial intelligence and biotechnology (AIxBio) sandbox;   

– A biotechnology roadmap for the DoD;  

– An assessment of biotechnology in the People’s Republic of China;  

– An intelligence strategy to counter biotechnology threats.  

  

The Commission worked with Congress to develop these proposals, which set the stage for further recommendations forthcoming in early 2025.

We are encouraged by this bipartisan and bicameral emphasis on biotechnology as a national security priority.  

  

Read more: https://lnkd.in/eTzjC5CC

https://www.biotech.senate.gov/press-releases/national-security-commission-on-emerging-biotechnology-announces-fy25-ndaa-biotechnology-provisions/

Https://www.stocktitan.net/news/HOPHF/hemogenyx-pharmaceuticals-plc-announces-notice-of-extraordinary-rbooio933nx6.html

The reorganization will affect holdings below 400 shares, potentially resulting in fractional entitlements.

Positive

-Strategic capital restructuring to attract institutional investors

-Potential to improve funding access for clinical trials

-Company at pivotal stage with recent equity capital injections

Negative

-Shareholders with less than 400 shares will lose their positions

-Urgent need for funding indicating financial pressure

-Dilution risk from potential 50% pre-emption rights disapplication

-Failure to pass resolutions would compromise clinical trial financing

It baffles me how much time some people in this board spend on picking on each other.

If you are smart enough to understand why someone posts certain messages, are you just in need of gratification ?

Let it go, some people have certain agenda, don't fuel it.

There's so much to look forward to in Hemo, in the near future.

CAR T finally in clinical stage it's huge in anyone's book.

New improved CDX is certainly enticing major pharmas to invest in both CAR T and CDX.

CBR presentation 1st week of December could potentially be massive given US government interest.

Interesting to see how the next few weeks pan out.

GLA

Https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2023-0930.html

A phase 1, multicenter, open-label study of cb-012, a CRISPR-edited allogeneic anti-cll-1 CAR-T cell therapy in patients with relapsed/refractory acute myeloid leukemia (amplify)

A phase 1, multicenter, open-label study of cb-012, a CRISPR-edited allogeneic anti-cll-1 CAR-T cell

Https://www.macroaxis.com/invest/advice/HOPHF#:~:text=Hemogenyx%20Pharmaceuticals%20Plc%20has%20accumulated,continue%20generating%20positive%20cash%20flow.

📢📢📢

👋👋

👀 👀

⏳️⏳️⏳️⏳️⏳️

⌛️⌛️⌛️⌛️⌛️

3-2-1....!!!!

🚀🚀🚀🚀🚀🚀🚀

Thanks for the Biography run through, interesting to what length some people go digging, perhaps a bit scary and intrusive to say the least, but whatever.

During my time as a LSE member, I've only posted 27 times and quite a lot of it was today.

If anything, what that tells you is that I am not a rambling person with verbal diarrhoea, going around trying to influence and convince people.

Just expressing my opinion, without going on and on and on and on, hyping a share because perhaps I missed on a rerate, talking about the price of gold every 5 minutes, or trying to force my opinion to anyone.

In case this has escaped to anyone, everything that has been thrown out to shareholders in ECR for a long time is theoretical, big statements with hyped up enthusiasm, but no actual results.

I'm invested here and I am as optimistic as the next guy, but sometimes it feels like my money is being used to fund someone's hobby for searching gold, the only difference

is that they are not using a simple metal detector.

I don't have hidden agenda, just once in a while saying as I see it.

Good luck to everyone

It seems like you have an obsession to want to convince people of your convictions and not willing to listen to an alternative argument.

As to your question,

How long can you hold your breath?

"It'll be sent to you as a signed confession, by the time you need another one."

Pathetic.

Pointless to further continue this with you TS,

It seems I hit a nerve.

Or perhaps I am talking to the same people I'm raising the question about.

Good luck to all invested, we'll be needing it.

Don't know about you TS, but I don't pay my bills with shares.

And, I don't know exactly how many shares each of those guys hold, but a quick glance at the RNSs gives you an idea. So, impact of selling that many on the SP has to be careful considered.

It's good and well to be supportive and enthusiastic about this shares, but not to the pathological extent.

A dose of reality is healthy.

BW

Alak

There's an argument to be made about the 90% remuneration some of the top guys are receiving as part of their salary.

It's been persisting for about 9 months. I'm sure they are well off and may not need the money, but continuing like this for quite a while, raises questions:

How long can they continue being paid like this?

Are we where we are , despite several reasonably good RNSs, because of possible sellings from them, and if not ,

What happens when and if they do decide to sell, for whatever reason? They could potentially collapse the market.

Something to consider.

"" Blue Mountain currently encompasses ‘a relatively straightforward alluvial gold system’ reported to contain at least 100,000 ounces. The ‘readily accessible’ system ‘presents the potential to accelerate the project towards “production-ready status” in the near future, subject to the necessary licensing permissions’. ECR says the site’s landowners ‘have expressed their willingness to work with us on the project which has further increased our confidence that the project could well exceed our initial expectations.’